<p>Telix Pharmaceuticals Limited（纳斯达克代码：TLX - 获取免费报告）在周三的交易中股价创下 52 周新低。该公司股价最低跌至 7.29 美元，最后交易价格为 7.26 美元，成交量为 11340 股。该股票此前收盘价为 7.73 美元。</p>
<p>获取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>多位股票研究分析师最近对 TLX 股票发表了评论。加拿大皇家银行在周一的研究报告中将 Telix Pharmaceuticals 的评级从 “持有” 上调至 “适度买入”。Wall Street Zen 在 12 月 20 日的报告中将 Telix Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并设定了 20.00 美元的目标价格。Canaccord Genuity Group 在 10 月 6 日的研究报告中将 Telix Pharmaceuticals 的评级上调至 “强力买入”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Telix Pharmaceuticals 的 “卖出（d）” 评级。一位研究分析师给予该股票 “强力买入” 评级，六位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 21.00 美元。</p>
<p><strong>获取我们关于 TLX 的最新研究报告</strong></p>
<h2>Telix Pharmaceuticals 价格表现</h2>
<p>该公司的 50 日移动平均价格为 8.56 美元，200 日移动平均价格为 10.46 美元。</p>
<h2>Telix Pharmaceuticals 的机构交易</h2>
<p>机构投资者和对冲基金最近买入和卖出了该公司的股票。Millennium Management LLC 在第三季度收购了 Telix Pharmaceuticals 的新股份，价值约 188.3 万美元。Pier Capital LLC 在第二季度收购了 Telix Pharmaceuticals 的新头寸，价值 303.7 万美元。Portland Investment Counsel Inc.在第三季度收购了 Telix Pharmaceuticals 的新头寸，价值 122.5 万美元。Lazard Asset Management LLC 在第三季度购买了 Telix Pharmaceuticals 的新头寸，价值约 109.7 万美元。最后，Russell Investments Group Ltd.在第二季度收购了 Telix Pharmaceuticals 的新股份，价值约 97.5 万美元。</p>
<h2>Telix Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Telix Pharmaceuticals（纳斯达克：TLX）是一家临床阶段的生物制药公司，专注于分子靶向放射药物的开发和商业化，用于癌症的诊断和治疗。Telix 利用在放射化学、核医学和肿瘤学方面的专业知识，旨在通过将诊断成像剂与治疗性放射性核素相结合，解决多种肿瘤类型未满足的临床需求。</p>
<p>该公司的产品线涵盖成像和治疗候选药物。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Telix Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普迄今为止最大的一项</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1000 美元于 Telix Pharmaceuticals 吗？</h2>
<p>在您考虑 Telix Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Telix Pharmaceuticals 并不在名单上。</p>
<p>虽然 Telix Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Telix Pharmaceuticals (NASDAQ:TLX) 的股价创下 52 周新低，达到 7.26 美元，较前一交易日的收盘价 7.73 美元下跌。分析师们的意见不一，加拿大皇家银行将该股票评级上调至 “适度买入”，而华尔街禅则将其下调至 “卖出”。平均分析师评级为 “适度买入”，目标价为 21.00 美元。机构投资者最近增加了对该公司的持股，该公司专注于开发用于癌症治疗的放射药物</p>

<p>Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $7.29 and last traded at $7.26, with a volume of 11340 shares trading hands. The stock had previously closed at $7.73.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals Limited（纳斯达克代码：TLX - 获取免费报告）在周三的交易中股价创下 52 周新低。该公司股价最低跌至 7.29 美元，最后交易价格为 7.26 美元，成交量为 11340 股。该股票此前收盘价为 7.73 美元。</p>
</div><p>Get <strong>Telix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts have recently commented on TLX shares. Royal Bank Of Canada raised Telix Pharmaceuticals from a &#34;hold&#34; rating to a &#34;moderate buy&#34; rating in a research report on Monday. Wall Street Zen cut shares of Telix Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, December 20th. HC Wainwright reissued a &#34;buy&#34; rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Monday, October 6th. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $21.00.</p>
<div class="lb-trans"><p>多位股票研究分析师最近对 TLX 股票发表了评论。加拿大皇家银行在周一的研究报告中将 Telix Pharmaceuticals 的评级从 “持有” 上调至 “适度买入”。Wall Street Zen 在 12 月 20 日的报告中将 Telix Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并设定了 20.00 美元的目标价格。Canaccord Genuity Group 在 10 月 6 日的研究报告中将 Telix Pharmaceuticals 的评级上调至 “强力买入”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Telix Pharmaceuticals 的 “卖出（d）” 评级。一位研究分析师给予该股票 “强力买入” 评级，六位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 21.00 美元。</p>
</div><p><strong>Get Our Latest Research Report on TLX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 TLX 的最新研究报告</strong></p>
</div><h2>Telix Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Telix Pharmaceuticals 价格表现</h2>
</div><p>The business's 50-day moving average price is $8.56 and its 200 day moving average price is $10.46.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 8.56 美元，200 日移动平均价格为 10.46 美元。</p>
</div><h2>Institutional Trading of Telix Pharmaceuticals</h2>
<div class="lb-trans"><h2>Telix Pharmaceuticals 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the third quarter valued at approximately $1,883,000. Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at $1,225,000. Lazard Asset Management LLC bought a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth about $975,000.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买入和卖出了该公司的股票。Millennium Management LLC 在第三季度收购了 Telix Pharmaceuticals 的新股份，价值约 188.3 万美元。Pier Capital LLC 在第二季度收购了 Telix Pharmaceuticals 的新头寸，价值 303.7 万美元。Portland Investment Counsel Inc.在第三季度收购了 Telix Pharmaceuticals 的新头寸，价值 122.5 万美元。Lazard Asset Management LLC 在第三季度购买了 Telix Pharmaceuticals 的新头寸，价值约 109.7 万美元。最后，Russell Investments Group Ltd.在第二季度收购了 Telix Pharmaceuticals 的新股份，价值约 97.5 万美元。</p>
</div><h2>Telix Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Telix Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals（纳斯达克：TLX）是一家临床阶段的生物制药公司，专注于分子靶向放射药物的开发和商业化，用于癌症的诊断和治疗。Telix 利用在放射化学、核医学和肿瘤学方面的专业知识，旨在通过将诊断成像剂与治疗性放射性核素相结合，解决多种肿瘤类型未满足的临床需求。</p>
</div><p>The company’s pipeline spans both imaging and therapeutic candidates.</p>
<div class="lb-trans"><p>该公司的产品线涵盖成像和治疗候选药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Telix Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Telix Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普迄今为止最大的一项</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Telix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1000 美元于 Telix Pharmaceuticals 吗？</h2>
</div><p>Before you consider Telix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Telix Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Telix Pharmaceuticals 并不在名单上。</p>
</div><p>While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Telix Pharmaceuticals 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Telix Pharmaceuticals（NASDAQ:TLX）创下 52 周新低 - 现在是卖出的时候吗？